Very long-term survival of an older glioblastoma patient after treatment with cilengitide: a case report
Glioblastoma (GBM) is the most common malignant brain tumor. Less than 1% of patients survive longer than 10 years. A 77-year-old woman was diagnosed with MGMT-methylated GBM in 2009. The patient received cilengitide as part of the CENTRIC clinical trial in conjunction with standard radiation and ch...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-06-01
|
| Series: | CNS Oncology |
| Subjects: | |
| Online Access: | https://www.futuremedicine.com/doi/10.2217/cns-2022-0017 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850152296363589632 |
|---|---|
| author | Huda Alalami Serguei Bannykh Xuemo Fan Jethro Hu |
| author_facet | Huda Alalami Serguei Bannykh Xuemo Fan Jethro Hu |
| author_sort | Huda Alalami |
| collection | DOAJ |
| description | Glioblastoma (GBM) is the most common malignant brain tumor. Less than 1% of patients survive longer than 10 years. A 77-year-old woman was diagnosed with MGMT-methylated GBM in 2009. The patient received cilengitide as part of the CENTRIC clinical trial in conjunction with standard radiation and chemotherapy. Though the study was halted in 2013, our patient received cilengitide until 2016 with no radiographic evidence of recurrence thus far. This is the oldest reported GBM patient with greater than 10-year survival. Her exceptional response may have been influenced by MGMT promoter methylation status and PTEN expression. |
| format | Article |
| id | doaj-art-28ebb3500d304458aaba657b448d58e4 |
| institution | OA Journals |
| issn | 2045-0907 2045-0915 |
| language | English |
| publishDate | 2023-06-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | CNS Oncology |
| spelling | doaj-art-28ebb3500d304458aaba657b448d58e42025-08-20T02:26:02ZengTaylor & Francis GroupCNS Oncology2045-09072045-09152023-06-0112210.2217/cns-2022-0017Very long-term survival of an older glioblastoma patient after treatment with cilengitide: a case reportHuda Alalami0Serguei Bannykh1Xuemo Fan2Jethro Hu31Neurology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA2Pathology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA2Pathology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA1Neurology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USAGlioblastoma (GBM) is the most common malignant brain tumor. Less than 1% of patients survive longer than 10 years. A 77-year-old woman was diagnosed with MGMT-methylated GBM in 2009. The patient received cilengitide as part of the CENTRIC clinical trial in conjunction with standard radiation and chemotherapy. Though the study was halted in 2013, our patient received cilengitide until 2016 with no radiographic evidence of recurrence thus far. This is the oldest reported GBM patient with greater than 10-year survival. Her exceptional response may have been influenced by MGMT promoter methylation status and PTEN expression.https://www.futuremedicine.com/doi/10.2217/cns-2022-0017biomarkercilengitideglioblastomaintegrinstreatment |
| spellingShingle | Huda Alalami Serguei Bannykh Xuemo Fan Jethro Hu Very long-term survival of an older glioblastoma patient after treatment with cilengitide: a case report CNS Oncology biomarker cilengitide glioblastoma integrins treatment |
| title | Very long-term survival of an older glioblastoma patient after treatment with cilengitide: a case report |
| title_full | Very long-term survival of an older glioblastoma patient after treatment with cilengitide: a case report |
| title_fullStr | Very long-term survival of an older glioblastoma patient after treatment with cilengitide: a case report |
| title_full_unstemmed | Very long-term survival of an older glioblastoma patient after treatment with cilengitide: a case report |
| title_short | Very long-term survival of an older glioblastoma patient after treatment with cilengitide: a case report |
| title_sort | very long term survival of an older glioblastoma patient after treatment with cilengitide a case report |
| topic | biomarker cilengitide glioblastoma integrins treatment |
| url | https://www.futuremedicine.com/doi/10.2217/cns-2022-0017 |
| work_keys_str_mv | AT hudaalalami verylongtermsurvivalofanolderglioblastomapatientaftertreatmentwithcilengitideacasereport AT sergueibannykh verylongtermsurvivalofanolderglioblastomapatientaftertreatmentwithcilengitideacasereport AT xuemofan verylongtermsurvivalofanolderglioblastomapatientaftertreatmentwithcilengitideacasereport AT jethrohu verylongtermsurvivalofanolderglioblastomapatientaftertreatmentwithcilengitideacasereport |